Professor Sir gregory Paul Winter was born in Leicester, U.K., in 1951, and brought up in West Africa. He went to Trinity College, Cambridge, and graduated from Cambridge University in 1973. He obtained his PhD in 1976, and completed a post-doctoral fellowship at the Imperial College in London, and a second post-doctoral fellowship at the Institute of genetics at Cambridge University. His Ph.D. and post-doctoral research involved protein sequencing and nucleic acid sequencing. He was joint Head of the Division of Protein and Nucleic Acids Chemistry (PNAC) of the Medical Research Council Laboratory of Molecular Biology (LMB) and is currently Deputy Director of the MRC center for Protein Engineering.
Sir gregory’s scientific career has almost entirely been based at LMB in Cambridge. He is one of the leading authorities in protein engineering. In the early 1980’s, he worked on engineering the enzyme tyrosyl tRNA synthetase (in collaboration with A, Frsht), and subsequently on the engineering of antibodies. In particular, he developed technologies for making humanized antibodies as well as making human antibodies in bacteria. He is the founder of Cambridge Antibody Technology (CAT), and the founder of Domantis. CAT discovered the first and one of the most successful fully human antibody drugs, HUMIRA, an antibody to TNF alpha, which was then developed and marketed by Abbot Laboratories, with sales of over $1 billion annually. In 2006, CAT was acquired by Astrazeneca while Domantis was acquired by glaxoSmithKline. Sir gregory’s research continues to be focused on protein and antibody engineering. All commercially manufactured antibodies that are currently used in molecular targeted therapy are based on Winter’s technology.
Sir gregory Winter authored numerous scientific publications and patents, especially with regards to humanized antibody technology and the use of antibody repertories and phage display technologies for making human antibodies in bacteria. His outstanding contributions in these fields were recognized by several awards and honors.
In addition to the King Faisal International Prize for Medicine, he received the William B. Coley Award of the Cancer Research Institute. He was also elected Fellow of the Royal Society (FRS), Fellow of the Academy of Medical Sciences, Honorary Fellow of the Royal College of Physicians and Fellow of Trinity College at Cambridge University. He is the Senior Editor of the journal Protein Engineering Design and Selection and a member of the editorial board of the European Journal of Immunology. Sir gregory is a Commander of the Order of the British Empire (CBE), and was knighted in 2004 for his services to Molecular Biology.
Dr. Winter, has been awarded the Prize, in recognition of his original and extremely’ important research in the field of molecular immunology. One of Winter’s most important achievements has been his success in developing “humanized” antibodies directly in the test tube, without the need for hybridoma and immunization of laboratory animals. His novel technique of in vitro production of antibodies paves the way for the development of new diagnostic procedures and therapeutic regimens, and several successful clinical trials have already been initiated along these lines